Remove 2021 Remove Disease Remove Trials
article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

NGS has revolutionised genomic analysis, enabling the identification of disease-related genetic variants. Clinical genomics, powered by NGS, enables more precise target validation, improved patient stratification and optimised trial design, ultimately aiming to increase PoS. Highlighting data integration. This is an AI generated image.

Drugs 64
article thumbnail

David Liu receives Breakthrough Prize in Life Sciences

Broad Institute

The organization has honored Liu for the development of the gene editing platforms base editing and prime editing, which can correct the vast majority of known disease-causing genetic variations and have already been used in at least 15 clinical trials, with life-saving results.

Science 144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Oncology advances through the lens of women in STEM

Drug Target Review

In addition to this, I also chaired national trials evaluating an anti-GD2 antibody in pediatric osteosarcoma. Working with one of the largest cooperative groups in pediatrics, the Children’s Oncology Group , we ran quick signal-seeking trials to determine efficacy.

article thumbnail

Time for change: non-human primates in drug research

Drug Target Review

Their unique suitability has made them valuable for evaluating pharmacokinetics, toxicology and safety in drug candidates before human clinical trials. Since 2021, institutions like the National Primate Research Centers (NPRCs) have reported their inability to meet up to two-thirds of requests for research monkeys.

article thumbnail

Inavolisib

New Drug Approvals

19] Society and culture Legal status In October 2024, the US Food and Drug Administration (FDA) approved inavolisib for the treatment of PIK3CA -mutant breast cancer based on the results from the INAVO120 trial. [3] Vanhaesebroeck B, Perry MW, Brown JR, Andr F, Okkenhaug K (October 2021). 22 June 2021. 3 November 2006.

FDA 57
article thumbnail

Risevistinel

New Drug Approvals

Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer’s disease, Parkinson’s disease, Lewy body disease. UNII-52TU5MZG22, X062KF5ZV3 (αS,4R)-α-[(1R)-1-Hydroxyethyl]-5-(2-methyl-1-oxopropyl)-1-oxo-2,5-diazaspiro[3.4]octane-2-acetamide

Disease 62
article thumbnail

Navigating Clinical Development Challenges to Advance Idiopathic Pulmonary Fibrosis Treatments

PPD

Patients diagnosed with idiopathic pulmonary fibrosis (IPF) — a progressive, rare lung disease marked by scarring and worsening lung function — often face a poor prognosis. While two approved treatments, pirfenidone and nintedanib, slow disease progression, there currently is no treatment that reverses the effects or offers a cure for IPF.